Relationship between phase angle, steatosis, and liver fibrosis in patients coinfected with human immunodeficiency virus/hepatitis C virus

Table 1 Anthropometric and clinical characteristics of the evaluated patients (n = 43) (mean ± SD)

Characteristic
Male sex, n (%)	22 (51.2)
Age, yr	46.2 ± 8.5
Body mass index	25.9 ± 4.9
Phase angle	7.1 ± 0.8
Lean mass, %	75.5 ± 9.2
Fatty mass, %	24.5 ± 9.2
Genotype HCV, n (%)
1	30 (69.7)
2	02 (4.7)
3	09 (20.9)
Missing data	02 (4.7)
Fibrosis, n (%)
F0	05 (11.6)
F1	10 (23.3)
F2	01 (2.3)
F3	10 (23.3)
F4	17 (39.5)
CAP	241.1 ± 55.7

CAP: Controlled attenuation parameter; HCV: Hepatitis C virus.

Table 2 Relationship between hepatic fibrosis and controlled attenuation parameter vs phase angle and lean mass (n = 43)

	Fibrosis1		CAP2
	rho	P value	r2	P value
Phase angle	0.075	0.634	0.016	0.918
Lean mass	0.095	0.543	0.4933	0.001

¹Spearman’s rho test.

²Pearson test.

³Correlation is significant at the 0.05 level (2-tailed).

CAP: Controlled attenuation parameter.

Table 3 Comparison between groups in accordance with fibrosis staging

	Fibrosis (TE < F3; n = 16)	Advanced fibrosis (TE ≥ F3; n = 27)	t-test	P value
Phase angle°	7.3° ± 1.0	7.0° ± 0.7	t (41) = 0.936	0.355
Lean mass (%)	73.9% ± 9.7	76.5 ± 8.9	t (41) = -0.89	0.378
Fatty mass (%)	26.1% ± 9.7	23.5% ± 8.9	t (41) = 0.886	0.381

Values are represented as mean ± SD. TE: Transient elastography.

Table 4 Relationship between phase angle and lean mass, fatty mass and controlled attenuation parameter

	Total (n = 43)		Males (n = 22)		Females (n = 21)
	r2	P value	r2	P value	r2	P value
Lean mass (%)	0.3731	0.014	0.208	0.353	0.189	0.412
Fatty mass (%)	-0.3731	0.014	-0.208	0.353	-0.189	0.411
CAP	0.016	0.918	0.035	0.878	0.102	0.659

¹Spearman’s rho test. Correlation is significant at the 0.05 level (2-tailed).

CAP: Controlled attenuation parameter.